Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Generics Bulletin

Medtech Insight

Drug Pricing: Could Expedited Review Of Competing Brands Create The Desired Pressure?

Jul 20 2017

• By Derrick Gingery

US dollars and pills

Related Content

User Fee Bill Or Drug Pricing Bill? House Members Makes Both Cases

Jul 13 2017

Brands Push Back Against REMS Reform, Call Problem Small With Burdensome Fixes

Jul 19 2017

FDA Exploring Whether Public Shaming Can Stop REMS Abuses

Jul 19 2017

FDA Drug Pricing Policy Offers Short-Term PR Gain, More Long-Term Actual Benefit

Jun 28 2017

Gilead Completes HCV Clinical Development With Vosevi Approval

Jul 18 2017

INFOGRAPHIC: Hepatitis C Market Still Has Room To Grow

Aug 01 2016

Gilead Faces Challenges In HCV, But Competitors Would Switch Places

Feb 12 2016

ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal

Sep 24 2016

Priority Review Vouchers Appear To Be Dropping In Price

Jul 27 2016

Related Companies

Gilead Sciences, Inc.

AbbVie Inc.

Additional Topics

United States Pricing Debate Generic Drugs Regulation FDA BioPharmaceutical

More from Generics

More from Products

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window